Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RECQL | P46063 | 1/20 | 0.39 |
| ▸ | CHRNB2 | P17787 | 11/20 | 0.35 |
| ▸ | CHRNB4 | P30926 | 11/20 | 0.35 |
| ▸ | CHRNA3 | P32297 | 11/20 | 0.35 |
| ▸ | CHRNA4 | P43681 | 11/20 | 0.35 |
| ▸ | CHRNA7 | P36544 | 10/20 | 0.35 |
| ▸ | PDK1 | Q15118 | 2/20 | 0.33 |
| ▸ | USP2 | O75604 | 1/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.33 |
| ▸ | REN | P00797 | 1/20 | 0.32 |
| ▸ | HPGD | P15428 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12208708 | 0.84 | RECQL (0.40) | RECQLPDK1USP2SMN1; SMN2HPGD | |
| SCHEMBL12233379 | 0.82 | PDK1 (0.35) | RECQLCHRNB2CHRNB4CHRNA3CHRNA4 | |
| SCHEMBL12208694 | 0.79 | SMN1; SMN2 (0.41) | RECQLCHRNB2CHRNB4CHRNA3CHRNA4 | |
| SCHEMBL1725473 | 0.79 | SMN1; SMN2 (0.41) | RECQLCHRNB2CHRNB4CHRNA3CHRNA4 | |
| SCHEMBL26125189 | 0.77 | PDK1 (0.51) | CHRNB2CHRNB4CHRNA3CHRNA4CHRNA7 | |
| SCHEMBL31655074 | 0.77 | PDK1 (0.51) | CHRNB2CHRNB4CHRNA3CHRNA4CHRNA7 | |
| SCHEMBL12208703 | 0.77 | SMN1; SMN2 (0.38) | RECQLPDK1USP2SMN1; SMN2 | |
| SCHEMBL14753009 | 0.77 | PDK1 (0.51) | CHRNB2CHRNB4CHRNA3CHRNA4CHRNA7 | |
| SCHEMBL12208699 | 0.76 | USP2 (0.37) | RECQLPDK1USP2SMN1; SMN2 | |
| SCHEMBL12331062 | 0.75 | CHRNB2 (0.41) | CHRNB2CHRNB4CHRNA3CHRNA4CHRNA7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20130060013-A1 | Compounds useful for treating neurodegenerative disorders | SATORI PHARMACEUTICALS, INC. (US) | 2013-03-07 | — | — | US | disclosed |
| US-20110251379-A1 | COMPOUNDS USEFUL FOR TREATING NEURODEGENERATIVE DISORDERS | SATORI PHARMACEUTICALS, INC. (US) | 2011-10-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130060013-A1 | Compounds useful for treating neurodegenerative disorders | SNCA, HTT, CLN6 | RECQL 1142/4885CHRNB2 122/4885CHRNB4 152/4885 |
| US-20110251379-A1 | COMPOUNDS USEFUL FOR TREATING NEURODEGENERATIVE DISORDERS | CLN6, NLN, ACHE | RECQL 528/4885CHRNB2 102/4885CHRNB4 129/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.